SecBot SecBot
8-K ·Filed Apr 8, 2026

PHIO

Phio Pharmaceuticals Corp.
NEUTRAL
Impact 5/10
Horizonweeks Processed7mo ago SEC0001437749-26-011761
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor for actual sales under this ATM program, as the $6.36 million represents a ceiling rather than a guaranteed amount. The capital will support PH-762 development but introduces dilution risk. Check future 10-Q filings for disclosure of shares sold and net proceeds received.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.25
T+0 close · Apr 8, 2026 · via day close
Latest settled
−20.80%
T+60 · $0.9900
Vs SPY
−31.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $1.25entry
  2. T+1 · 7mo ago −3.20%α −3.14% · $1.21
  3. T+5 · 7mo ago +1.60%α −1.59% · $1.27
  4. T+20 · 6mo ago −8.00%α −15.57% · $1.15
  5. T+60 · 4mo ago −20.80%α −31.58% · $0.9900
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock. This capital raise follows a recent shelf registration and is intended to fund development of PH-762 and general working capital. The offering introduces potential near-term dilution.

Key Financial Metrics

Deal Value
$6.4M

Key Facts

  • Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 million in common stock
  • The offering is being conducted pursuant to a shelf registration statement declared effective on July 1, 2024
  • Proceeds will be used to advance PH-762 into a Phase 2b/3 trial and for general working capital
  • H.C. Wainwright will receive a 3.0% commission on gross proceeds from sales
  • The company has no obligation to sell any shares and may suspend or terminate the offering at any time

Financial Impact

Up to $6.36 million in potential proceeds, with 3.0% commission paid to the placement agent

dilutioncashworking capital

Risk Factors

  • Dilution to existing shareholders if the full $6.36 million is raised
  • Potential downward pressure on stock price from incremental share issuance
  • No assurance that any shares will be sold under the agreement

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-011761
Exhibit: ex_942764.htm0001437749-26-011761
Document: phio20260402_8k.htm0001437749-26-011761
Document: 0001437749-26-011761-index-headers.html0001437749-26-011761
Document: 0001437749-26-011761-index.html0001437749-26-011761
Document: 0001437749-26-011761.txt0001437749-26-011761

Track record

7 reports on PHIO

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.8013 to $0.7710 Now $0.7520 +6.15% ▲ +3.78% +6.38% vs SPY
  2. Oct 13, 20264w ago 8-K Neutral 3/10 Entry $0.9345 to $0.8921 Now $0.7520 −19.53% ▼ −4.54% −3.39% vs SPY
  3. Sep 14, 20269w ago 8-K Bullish 5/10 Entry $1.03 to $1.01 Now $0.7520 −26.99% ▼ −1.94% −2.05% vs SPY
  4. Aug 14, 202613w ago DEFA14A Neutral 3/10 Entry $1.06 to $1.17 Now $0.7520 −29.06% ▲ +10.38% +11.57% vs SPY
  5. Apr 8, 202631w ago 8-K Neutral 5/10 Viewing Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
  6. Apr 8, 202631w ago 424B5 Neutral 5/10 Entry $1.25 to $1.27 Now $0.7520 −39.84% ▲ +1.60% −1.59% vs SPY
  7. Mar 5, 202636w ago 8-K Mixed 6/10 Entry $1.16 to $1.17 Now $0.7520 −35.17% ▲ +0.86% +2.39% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026